Seattle Genetics, Inc.

Pacific Northwest Research Institute

Other

University of Washington

Fred Hutchinson Cancer Center

Nathalie Scholler

Karl E Hellstrom

Ingegerd E Hellstrom

Alan F Wahl

Linda Anne Pestano

Che-Leung Law

Mary L Disis

Cheu-leung Law

Barbara Garvik

Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing a cancer, comprising administering to a subject the disclosed pharmaceutical compositions.

Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates

Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of a CD70-expressing cancer, comprising administering to a subject the disclosed pharmaceutical compositions.

Treatment of B-cell cancers with anti-CD70 antibody-drug conjugates

Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.

Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders

The present invention provides compositions and methods for generating in vivo biotinylated, secreted recombinant polypeptides comprising recombinantly co-expressing in a yeast cell (a) a secreted recombinant polypeptide comprising a biotin accepting site; and (b) a biotin ligase fused to the golgi localization domain so that the biotin ligase is localized to the golgi of the yeast cell where it acts on the biotin-accepting site of the secreted polypeptide as it transits the secretory system.

Vectors for expressing in vivo biotinylated recombinant proteins

The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.

Methods and compositions for diagnosing carcinomas

Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders

The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.

Growing community of inventors

Seattle, WA, United States of America

Nathalie Scholler